

Pluvicto is a prostate cancer targeted radiotherapy that is injected into a patient systemically and then rapidly localizes to prostate cancer cells, thereby killing the cancer cells with minimal if any toxicity to healthy cells. Clinical data show that Pluvicto reduces the risk of disease progression or death by 60% compared to previous therapies.

